June 15, 2023
3 min watch
Save
VIDEO: COMMANDS study shows luspatercept as option for low-risk myelodysplastic syndrome
In this video, Eunice Wang, MD, discussed the results of the phase 3 COMMANDS study, pertaining to low-risk myelodysplastic syndrome, presented at ASCO Annual Meeting.
Wang, chief of the leukemia service at Roswell Park Comprehensive Cancer Center, highlighted the study, which presented data suggesting that luspatercept (Reblozyl; Celgene, Bristol Myers Squibb) could improve quality of life in place of or addition to erythropoiesis-stimulating agent therapy.
“We’re looking forward to having this as another agent in our armamentarium for lower-risk patients,” Wang said.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Wang reports consulting, advising and speaking for AbbVie, Amgen, Astellas, Bristol Myers Squibb, CTI Biopharm, Daiichi Sankyo, Gilead, GSK, Janssen, Jazz Pharmaceuticals, Kite Pharma, Kura Oncology, Novartis, Pfizer, PharmaEssentia, Rigel, Sellas, Stemline and Sumitomo Pharma.
Read more about